- Home
- RIGL vs LINC Comparison
RIGL vs LINC Comparison
Compare RIGL & LINC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | LINC |
|---|---|---|
| Founded | 1996 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.4M | 732.0M |
| IPO Year | 2000 | 2005 |
Fundamental Metrics
Financial Performance| Metric | RIGL | LINC |
|---|---|---|
| Price | $34.56 | $36.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $43.20 | $37.50 |
| AVG Volume (30 Days) | 257.9K | ★ 472.4K |
| Earning Date | 04-01-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 807.14 | N/A |
| EPS | ★ 5.38 | 0.23 |
| Revenue | $179,278,000.00 | ★ $261,853,000.00 |
| Revenue This Year | $66.81 | $9.55 |
| Revenue Next Year | N/A | $8.13 |
| P/E Ratio | ★ $6.66 | $150.39 |
| Revenue Growth | ★ 53.38 | 32.98 |
| 52 Week Low | $15.50 | $14.10 |
| 52 Week High | $52.24 | $36.42 |
Technical Indicators
Market Signals| Indicator | RIGL | LINC |
|---|---|---|
| Relative Strength Index (RSI) | 44.17 | 77.68 |
| Support Level | $33.05 | $21.46 |
| Resistance Level | $36.95 | N/A |
| Average True Range (ATR) | 1.46 | 1.86 |
| MACD | 0.24 | 0.72 |
| Stochastic Oscillator | 39.78 | 98.17 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About LINC Lincoln Educational Services Corporation
Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services, and business and information technology. Its reportable segments include; Campus Operations, and Transitional. The majority of the revenue is generated from the Campus Operations segment which includes all campuses that are continuing in operation and contribute to the Company's core operations and performance.